These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 17762434

  • 1. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results.
    Patt YZ, Lee FC, Liebmann JE, Diamandidis D, Eckhardt SG, Javle M, Justice GR, Keiser W, Salvatore JR, Bexon A, Lin E.
    Am J Clin Oncol; 2007 Aug; 30(4):350-7. PubMed ID: 17762434
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
    Ducreux M, Adenis A, Pignon JP, François E, Chauffert B, Ichanté JL, Boucher E, Ychou M, Pierga JY, Montoto-Grillot C, Conroy T.
    Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
    [Abstract] [Full Text] [Related]

  • 3. Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
    Cartwright T, Kuefler P, Cohn A, Hyman W, Berger M, Richards D, Vukelja S, Nugent JE, Ruxer RL, Boehm KA, Asmar L.
    Clin Colorectal Cancer; 2008 Nov; 7(6):390-7. PubMed ID: 19036692
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.
    Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M, Chin K, Yamaguchi T.
    Drug Des Devel Ther; 2015 Nov; 9():1653-62. PubMed ID: 25834402
    [Abstract] [Full Text] [Related]

  • 6. Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials.
    García Alfonso P, Muñoz Martin A, Alvarez Suarez S, Blanco Codeidido M, Mondejar Solis R, Tapia Rico G, López Martín P, Martin M.
    Onkologie; 2013 Nov; 36(6):363-7. PubMed ID: 23774151
    [Abstract] [Full Text] [Related]

  • 7. Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients.
    Li W, Xu J, Shen L, Liu T, Guo W, Zhang W, Chen Z, Zhu X, Li J.
    BMC Cancer; 2014 Dec 19; 14():986. PubMed ID: 25527007
    [Abstract] [Full Text] [Related]

  • 8. The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer.
    Shin SJ, Ahn JB, Choi HJ, Cho BC, Jeung HC, Rha SY, Chung HC, Roh JK.
    Cancer Chemother Pharmacol; 2008 Jan 19; 61(1):75-81. PubMed ID: 17375304
    [Abstract] [Full Text] [Related]

  • 9. XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.
    Uygun K, Bilici A, Kaya S, Oven Ustaalioglu BB, Yildiz R, Temiz S, Seker M, Aksu G, Cabuk D, Gumus M.
    Asian Pac J Cancer Prev; 2013 Jan 19; 14(4):2283-8. PubMed ID: 23725128
    [Abstract] [Full Text] [Related]

  • 10. Capecitabine plus irinotecan versus 5-FU/leucovorin plus irinotecan in the treatment of colorectal cancer: a meta-analysis.
    Guo Y, Shi M, Shen X, Yang C, Yang L, Zhang J.
    Clin Colorectal Cancer; 2014 Jun 19; 13(2):110-8. PubMed ID: 24461997
    [Abstract] [Full Text] [Related]

  • 11. A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study).
    Hamamoto Y, Yamaguchi T, Nishina T, Yamazaki K, Ura T, Nakajima T, Goto A, Shimada K, Nakayama N, Sakamoto J, Morita S, Yamada Y.
    Oncologist; 2014 Nov 19; 19(11):1131-2. PubMed ID: 25280489
    [Abstract] [Full Text] [Related]

  • 12. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
    Bennouna J, Borg C, Delord JP, Husseini F, Trillet-Lenoir V, Faroux R, François E, Ychou M, Goldwasser F, Bouché O, Senellart H, Kraemer S, Douillard JY.
    Clin Colorectal Cancer; 2012 Mar 19; 11(1):38-44. PubMed ID: 21803002
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic or advanced colorectal carcinoma--a dual-centre phase II study: the MAC-6.
    Choi CK, Chan RT, Tung SY, Lui L, Siu S, Au GK, Ho JW, Law WL.
    Clin Oncol (R Coll Radiol); 2008 Mar 19; 20(2):168-75. PubMed ID: 18155454
    [Abstract] [Full Text] [Related]

  • 14. A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer.
    Renouf DJ, Welch S, Moore MJ, Krzyzanowska MK, Knox J, Feld R, Liu G, MacKay H, Petronis J, Wang L, Chen E.
    Cancer Chemother Pharmacol; 2012 May 19; 69(5):1339-44. PubMed ID: 22349811
    [Abstract] [Full Text] [Related]

  • 15. Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study.
    Hofheinz RD, Gnad-Vogt U, Wein A, Saussele S, Kreil S, Pilz L, Hehlmann R, Hochhaus A.
    Anticancer Drugs; 2005 Jan 19; 16(1):39-45. PubMed ID: 15613902
    [Abstract] [Full Text] [Related]

  • 16. Irinotecan plus capecitabine as first-line chemotherapy in advanced colorectal cancer.
    Gennatas C, Michalaki V, Gennatas S, Papalambros E.
    Anticancer Res; 2008 Jan 19; 28(3B):1923-6. PubMed ID: 18630482
    [Abstract] [Full Text] [Related]

  • 17. Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab.
    Kotaka M, Xu R, Muro K, Park YS, Morita S, Iwasa S, Uetake H, Nishina T, Nozawa H, Matsumoto H, Yamazaki K, Han SW, Wang W, Ahn JB, Deng Y, Cho SH, Ba Y, Lee KW, Zhang T, Satoh T, Buyse ME, Ryoo BY, Shen L, Sakamoto J, Kim TW.
    Chin J Cancer; 2016 Dec 22; 35(1):102. PubMed ID: 28007025
    [Abstract] [Full Text] [Related]

  • 18. Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group.
    Garcia-Alfonso P, Muñoz-Martin A, Mendez-Ureña M, Quiben-Pereira R, Gonzalez-Flores E, Perez-Manga G.
    Br J Cancer; 2009 Oct 06; 101(7):1039-43. PubMed ID: 19738605
    [Abstract] [Full Text] [Related]

  • 19. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
    Comella P, Natale D, Farris A, Gambardella A, Maiorino L, Massidda B, Casaretti R, Tafuto S, Lorusso V, Leo S, Cannone M.
    Cancer; 2005 Jul 15; 104(2):282-9. PubMed ID: 15948167
    [Abstract] [Full Text] [Related]

  • 20. A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer.
    Sato Y, Ohnuma H, Hirakawa M, Takahashi M, Osuga T, Okagawa Y, Murase K, Takada K, Kawano Y, Iyama S, Hayashi T, Sato T, Miyanishi K, Takimoto R, Kobune M, Okita K, Mizuguchi T, Furuhata T, Hirata K, Kato J.
    Cancer Chemother Pharmacol; 2015 Mar 15; 75(3):587-94. PubMed ID: 25577134
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.